(서울=NSP통신) jeong seop park Jour = Ckexogene, a Korean bio drug development company, plans to develop ‘exosome based arthritis drug’, according to a company announcement.
The company has already developed a covid 19 vaccine for clinical trial(Exosome covid 19 vaccine - CKV21) and started to produce the drug.
The drug, the world’s first exosome Covid 19 vaccine, expressed antibody just with one administration in a non-clinical trial.
The company said the arthritis drug to be developed will be the innovative treatment because it is based on the exosome technology, the first in the world.
The company plans to announce its development plans, including commercialization paln and achievements on the international medical journals and hold a seminar in the second half of this year.
NSP News Agency jeong seop park Journalist firstname.lastname@example.org
Copyright ⓒ Korea's economic news agency NSP NEWS·NSP TV. All rights reserved-Redistribution Prohibited.